National Institutes of Health (NIH)
NEWS
UH Biologist Discovers Protein Partnership That Protects Blood Vessels
Examples of new syndromes include hypotonia, ataxia, and delayed development syndrome (HADDS) and Sashi-Pena syndrome (SHAPNS).
Gamida Cell Ltd. filed for a $69 million initial public offering for the Nasdaq exchange, according to a filing submitted last week to the U.S. Securities and Exchange Commission, Israel’s Calcalist first reported last week.
Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.
Politicians might deny climate change, but disease-carrying insects and their pathogens aren’t—they’re exploiting it.
The U.S. Food and Drug Administration is hoping to fill numerous vacancies at the regulatory agency. In June, the FDA laid out some of its hiring needs, as well as its approach to attracting top-quality talent in a report to Congress.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureTech Ventures, responded to the editorial in Forbes. Let’s take a look.
Citing safety concerns, a watchdog organization is calling on the National institutes of Health to halt enrollment in a clinical trial evaluating a treatment for sepsis that the organization said is risky and flawed.
JOBS
IN THE PRESS